ClinicalTrials.gg
RecruitingNCT05958940Updated Jan 9, 2025

BioClock: Bright Light Therapy for Depressive Disorders

An interventional study of Bright Light Therapy and Blue Light Blocking Glasses in Depression, Unipolar and Depression, Bipolar, sponsored by Universiteit Leiden. Recruiting at 2 sites in Netherlands. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-01-09.

Sponsored by Universiteit Leiden · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
231
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Depressive Disorder with a site in Netherlands — 7 open to participants now, 9 under way, none of them phase 3. Depressive Disorder · Netherlands.

Planned enrollment
4th of 16
231 · median 151
Started
2024
with 1 other
No phase
9 of 18
6 open now
Registered
15th of 18
by date

Among the 18 studies in Depressive Disorder with a site in Netherlands, this one is the 4th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2024, is one of 9 with no phase, and was the 15th registered.

Depressive Disorder

857 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.

Browse Depressive Disorder studies →

Open to participants now

7 of the 18 studies in Depressive Disorder with a site in Netherlands are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Depressive Disorder with a site in Netherlands, or all of them as a file.
02

Study summary

Bright Light Therapy (BLT) is a proven treatment for depression in seasonal and non-seasonal depressive disorders, as well as bipolar disorder. To make BLT more effective and practical in clinical settings and tailor it to individual needs, it is necessary to optimize the treatment approach, understand how the treatment works, and identify patient characteristics that predict response.

This clinical trial has three main goals:

  • Optimize the administration of BLT for patients with depressive episodes.
  • Gain a deeper understanding of the treatment mechanisms.
  • Determine which patients benefit the most from the treatment.

The specific objectives are as follows:

  • Investigate whether additional treatments and interventions related to lifestyle and the biological clock can enhance the effects of BLT.
  • Examine how BLT influences the body's internal clock and sleep quality, and how these factors contribute to the outcomes.
  • Identify patient characteristics and behaviours that can predict treatment outcomes.
  • Develop a brain model to better understand the impact of BLT on the brain.

In this study, patients will receive BLT with a light intensity of 10,000 lux for 30 minutes each morning over 5 consecutive days. The treatment duration will range from one to three weeks, depending on the improvement of depressive symptoms. Participants will be randomly assigned to one of three groups:

  • Home - Patients will receive BLT at home, following the standard guidelines for light therapy in the Netherlands.
  • LightCafé, fixed time: Patients will receive BLT in a café-like setting called the LightCafé, where the focus is not only on symptom improvement but also lifestyle enhancements and fostering social connections. The treatment time will be the same every day.
  • LightCafé, varying time: Patients will also receive BLT at the LightCafé, with treatment timing varying each day. Additionally, this group will wear glasses in the evening that filter blue light.

The study includes a baseline phase of up to two weeks, a treatment phase of up to three weeks, and a three-month follow-up phase. Patients will wear a motion watch to assess sleep-wake behaviour and physical activity during the day. Additionally, they will wear a broach that measures their personal light exposure throughout the day. Eight one-minute questionnaires per day will be sent to the participants' smartphones to assess vitality, sleep, and mood during the treatment. Predictors of treatment response, such as clinical characteristics, sleep measures, circadian parameters, and light-related behaviours, will be evaluated at baseline. In a small group of patients, salivary melatonin curves will be assessed before and after treatment. MRI scans will provide insights into functional and structural brain changes following light therapy treatment.

03

Conditions studied

  • Depression, Unipolar
  • Depression, Bipolar

Keywords

  • Depression
  • Bright Light Therapy
  • Chronotherapy
  • Circadian Rhythm
  • Sleep
  • Life Style
  • Ecological Momentary Assessment
  • Actigraphy
  • Dim light melatonin onset
  • Response predictors
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 65.
  • Diagnosis of unipolar or bipolar depression (seasonal or non-seasonal) as assessed with the Mini-International Neuropsychiatric Interview (M.I.N.I.)
  • A current depressive episode (a score of 6 or higher on the Quick Inventory of depressive symptomatology Self Report (QIDS-SR)
  • Sufficient knowledge of Dutch or English language to fill in questionnaires
  • Provided

Exclusion criteria

Exclusion Criteria:

  • A current (hypo)manic or mixed episode (as assessed with the M.I.N.I.)
  • Current psychotic episode (as assessed with the M.I.N.I.)
  • Prominent active suicidality (score 10 or higher on the M.I.N.I. module)
  • Antidepressant therapy (medication, psychotherapy or BLT, or other forms of specific treatments for depression) that started less than 2 months prior to study entry
  • participants with bipolar disorder should be in mood-stabilizing treatment for at least 1 month in a recommended dosage,
  • Use of melatonin or agomelatine in the last month
  • Current use of antibiotics
  • Current use of light sensitivity increasing medication
  • Travelled across more than 1 time zone during past month or during the treatment
  • Travelled to sunny holiday locations/winter sports during past month
  • pre-existing eye and skin disorders (retinitis pigmentosa, porphyria, chronic actinic dermatitis and sun-induced urticaria)
  • Systemic disorders with potential retinal involvement (rheumatoid arthritis and systemic lupus erythematosus)
  • Suffering from colour blindness (assessed by Ishihara colour plates)
  • Participated in night shift work in the last three months
  • (Retinal) blindness, severe cataract and glaucoma
  • Light-induced migraine or epilepsy
  • Pregnancy, or parents with a child younger than 18 months old
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
231 participants (estimated)

Study arms

  • Active comparator
    Light@Home

    Standard Care - BLT in the home environment

    Procedure: Bright Light Therapy

  • Experimental
    LightCafé

    BLT will be administered in a specialized cafe, under the supervision of clinical staff, promoting lifestyle changes and social interaction.

    Procedure: Bright Light Therapy

  • Experimental
    LightCafé+

    Treatment will be identical to the second arm but now complemented with the use of blue-light blocking glasses in the evening and the adoption of personalized BLT timing based on sleep-wake patterns

    Procedure: Bright Light Therapy · Device: Blue Light Blocking Glasses

Interventions

  • ProcedureBright Light Therapy

    In this study, Bright Light Therapy (BLT) will be administered according to Dutch depression guidelines, using Innolux LED light lamp (3800K, 10,000 lux). BLT will be given for one work week (Mon-Fri), 7:30-10:30 AM, 30 mins/session. Patients can have breakfast, read, or use devices. Treatment effectiveness will be evaluated using Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). If remission is achieved (QIDS-SR \< 6), no additional treatment is given. If response is insufficient (QIDS-SR ≥ 6), 5 more sessions will be added in the following week, with maximum two extensions (1-3 weeks total).

  • DeviceBlue Light Blocking Glasses

    Plastic, orange-coloured glasses that primarily block blue light. To be worn in the evening.

06

What researchers measure

Primary outcomes

  1. Clinical Improvement

    Difference between pre- and post-treatment assessment of the Montgomery Asberg Depression Rating Scale \[MADRS\]

    Time frame: 2-5 weeks

Secondary outcomes

  1. Subjective change in depressive symptom severity

    Change in score on the Quick Inventory of Depressive Symptoms, Self Report (QIDS-SR)

    Time frame: from baseline until follow-up, approximately 4 months

  2. Remission rates, self assessed and clinician rated

    percentage of patients that after treatment have a score of \<6 on the MADRS or QIDS-SR

    Time frame: 2-5 weeks for clinician rated. Up until 4 months after start treatment for self-assessed

  3. Response Rates, self assessed and clinician rated

    percentage of patients hat after treatment have at least 50% reduction in depressive symptom, measured using MADRS and QIDS-SR

    Time frame: 2-5 weeks for clinician rated, Up until 4 months after start treatment for self-assessed

  4. Time to remission

    The time it takes to achieve remission, if remission is achieved. Measured with QIDS-SR

    Time frame: one, two or three weeks

  5. Circadian phase

    Changes in circadian phase will be compared between groups as assessed using the DLMO (calculated from the melatonin assessments) and complemented with actigraphy data (using sleep onset timing, least active 5h period and most active 10h period)

    Time frame: 2-5 weeks

  6. Circadian amplitude

    Changes in the circadian amplitude will be compared between groups. The amplitude can be estimated from actigraphy data by the difference in activity between the most active 10h and the least active 5h normalized for total activity.

    Time frame: 2-5 weeks

  7. Circadian Periodicity

    Changes in circadian periodicity will be compared between groups. Circadian periodicity is a period of an oscillating rhythm assessed via periodogram analysis of the activity time-course of actigraphy data. The deviation between the maximum period of the periodogram and the normal daily period of 24h reflects pattern variability in normal entrainment conditions.

    Time frame: 2-5 weeks

  8. Inter-daily stability

    Constancy of the 24-h rhythmic pattern over days

    Time frame: 2-5 weeks

  9. Intra-daily variability

    rhythm fragmentation

    Time frame: 2-5 weeks

  10. Chronotype

    Chronotype changes as assessed with the Morningness-Eveningness Questionnaire(MEQ) and the Ultra-Short Version of the Munich Chronotype Questionnaire (µMCTQ)

    Time frame: 1-3 months

  11. Sleep-Wake Pattern

    Actigraphy and questions from The Consensus Sleep Diary will provide sleep onset time, sleep offset time, midsleep time, total sleep time, sleep onset latency, number of awakenings and time awake during the night.

    Time frame: 2-5 weeks

  12. Sleep Quality

    Fragmentation index (degree of movement during the night), sleep efficiency (total sleep time expressed as a percentage of time in bed) will be calculated using actigraphy data. The Pittsburgh Sleep Quality Index (PSQI) will provide a subjective measure of sleep quality.

    Time frame: 2-5 weeks for actigraphy, up until 4 months after the start of treatment for subjective sleep quality

  13. Severity of Insomnia Symptoms

    Severity of Insomnia Symptoms as assessed with the Insomnia Severity Index

    Time frame: up until 4 months after the starts of treatment

  14. Momentary Positive/Negative Affect

    The EMA will consist of items from the Positive and Negative Affect Scale (PANAS) to assess momentary positive and negative affect

    Time frame: 2-5 weeks

  15. Momentary Vitality

    The EMA will contain 4 items concerning energy levels and alertness adapted from Activation-Deactivation Adjective Checklist

    Time frame: 2-5 weeks

  16. Gray matter structure

    Properties of gray matter structure (thickness, volume, surface area and gyrification) of the whole brain as well as of the white matter structure (integrity of main white matter fiber tracts-fractional anisotropy (FA))

    Time frame: 2-5 weeks

  17. Functional connectivity of the brain

    Functional connectivity of the brain under resting state condition - the communication of specific brain regions which work as a network without conducting a specific task

    Time frame: 2-5 weeks

Other outcomes

  1. Personal daily light exposure

    the percentage of time exposed to light above the threshold of 300 lux will be calculated from light sensor data as well as the mean timing thereof (MLiT100). Additional parameter might be extracted from the light exposure data based on state of the art procedures.

    Time frame: 2-5 weeks

  2. Treatment expectations

    Treatment expectations will be assessed using the Credibility/expectancy Questionnaire

    Time frame: baseline

  3. Light Induced Melatonin suppression

    Light Induced Melatonin suppression as assessed using the salivary melatonin assessments will give insight into light sensitivity of the participants.

    Time frame: Baseline

  4. Treatment Adherence

    Treatment adherence will be assessed subjectively using an item in the EMA and objectively using light logger devices.

    Time frame: 1-3 weeks

  5. Side Effects

    Side effects will be monitored with a questionnaire based on the Toronto Side Effects Questionnaire

    Time frame: 1-3 weeks

07

Study locations

2 of 2 sites recruiting
  • GGzE - Mental Health Institute of Eindhoven and the Kempen
    Eindhoven, 5626 ND, Netherlands
    Recruiting
  • Leids Universitair Behandel- en Expertise Centrum
    Leiden, 5626 ND, Netherlands
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All data underlying a publication can be shared upon request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Data will be available after publication of the analyses

Access criteria: Access may be granted to researchers who intend to conduct secondary analyses or meta-analyses using individual participant data. Additionally, researchers with a valid scientific research question or hypothesis that aligns with the objectives of the original study may be considered for IPD access.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Sep 2026, 31 months after the start.

Of 261 non-industry interventional studies with no phase under Depressive Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 45. This study's planned 31 months is close to that.

Counting every sponsor, half of 276 studies reached it within 29 months; a quarter within 15 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2023
First posted
Jul 25, 2023
StartActual
Feb 8, 2024
Primary completionEst.
Sep 2026
CompletionEst.
Dec 2026
Last update
Jan 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05958940
Lead sponsor
Universiteit Leiden
Collaborators
Eindhoven University of Technology, Geestelijke Gezondheidszorg Eindhoven (GGzE), Chrono@Work B.V.
Responsible party
Niki Antypa (Associate Professor, Universiteit Leiden) — Principal investigator
First posted
Jul 25, 2023
Start date
Feb 8, 2024
Primary completion
Sep 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 9, 2025

Study contacts

Niki Antypa, PhD
Contact
nantypa@fsw.leidenuniv.nl
+31 71 527 6677
Luc Schlangen, PhD
Contact
Niki Antypa, PhD
principal investigator · Leiden University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion